310. 先天異常症候群 Congenital anomalies syndrome Clinical trials / Disease details
臨床試験数 : 11 / 薬物数 : 20 - (DrugBank : 10) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01434745 (ClinicalTrials.gov) | September 2011 | 7/9/2011 | SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation | Smith-Lemli Opitz Syndrome: A Clinical Investigation of the Effect of Simvastatin in Patients Receiving Cholesterol Supplementation | Smith-Lemli-Opitz Syndrome | Drug: Simvastatin;Dietary Supplement: Lactose | Oregon Health and Science University | National Heart, Lung, and Blood Institute (NHLBI) | Terminated | 1 Year | 89 Years | All | 1 | N/A | United States |
| 2 | NCT00064792 (ClinicalTrials.gov) | July 2003 | 11/7/2003 | Simvastatin Therapy in Smith-Lemli-Opitz Syndrome | Investigation of Simvastatin Therapy in Smith-Lemli-Opitz Syndrome | Smith-Lemli-Opitz Syndrome | Drug: Simvastatin Susp.;Drug: OraPlus | Forbes Porter, M.D. | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | 4 Years | 18 Years | All | 23 | Phase 2 | United States |